News
The Augurex team brings together leading scientific, clinical, technical and commercial expertise to ensure that our research translates into advanced diagnostics for improved patient outcomes.
Natalie Dakers: Chair of Augurex’s Board of Directors Receives 2019 Milton Wong Award
Augurex is very proud to announce that Natalie Dakers, Chair of our Board of Directors, has been awarded the 2019 Milton Wong Award. Natalie’s award is well-deserved given her outstanding leadership and notable impact on the Life Sciences ecosystem, which Augurex has...
USPTO Awards Another Patent; New Data Demonstrating 14-3-3η as a Biomarker for Monitoring Therapy Response
USPTO Awards Patent for Citrullinated 14-3-3: Expanding Augurex's Portfolio in the Diagnosis of Rheumatoid Arthritis (RA) On November 20th, 2018 the US Patent and Trademark Office (USPTO) awarded patent number 10,132,806 entitled “Antigens Derived From Citrullinated...
Augurex and Quidel at ACR
Augurex and Quidel are pleased to announce the launch of the JOINTstat® 14-3-3η RUO (research use only) ELISA. This new distribution arrangement will get 14-3-3η testing into the hands of more investigators worldwide, including key opinion leaders and pharmaceutical...
More Precise RA Patient Care; New data on the 14-3-3η blood test to help optimize treat-to-target strategies
At the annual European congress of rheumatology meeting, The European League Against Rheumatism (EULAR), taking place in Amsterdam on June 13th-16th, leading investigators from United States, Israel, and Egypt will present new data on the 14-3-3η blood test. Several...
Digital Technology Supercluster Member Spotlight
Did you miss the Digital Technology Supercluster Member Spotlight on Augurex? Read how Augurex will be working alongside Supercluster members like Telus Health, Providence Health Care, Microsoft and LifeLabs Medical Laboratory Services to advance patient-centric...
B.C.’s Most Influential Women 2018: Stem Stars
Working in STEM means that you’re innovative, you’re creative, you’re passionate, you’re clever, you’re whoever you want to be. We're so proud of our CEO Norma Biln being recognized by BC Business as a vital contributor to Women in Tech: [button...
2018 Ready to Rocket Winner
Honored to be recognized by "Ready to Rocket" as one of the 10 featured Life Sciences companies to experience accelerated growth. We're excited for the future! About Ready to Rocket: Ready to Rocket is a unique business recognition list that profiles technology...
High 14-3-3η Amplifies the Risk of Rapid Radiographic Progression
In a study of over 800 rheumatoid arthritis (RA) patients, presented this week at the Canadian Rheumatology (CRA) Association Meeting, it was shown that a positive 14-3-3η blood test amplified the risk of rapid joint damage progression when added to current measures....
BC-Led Digital Technology Supercluster Awarded Federal Funding to Transform Canada’s Fastest-Growing Tech Sector
As a founding member, we are thrilled that the BC-led #DigitalSupercluster has been chosen. Truly an exciting day for technology innovation in Canada!
Exciting Update From the World of BC Biotechnology
When early discoveries are made at universities, they usually require additional research and funding to uncover what the innovation's clinical usefulness will be to patients and physicians. For example, in 2006 researchers at the University of British Columbia (Dr....
Protein Measured by a Blood Test Marks Joint Erosions in Arthritis
At Europe's premier arthritis congress, the European League Against Rheumatism (EULAR) last week in Berlin, researchers presented findings that a protein measurable in blood named 14-3-3η, marks the presence of joint damage in two different forms of arthritis,...
Novel Blood Test Identifies Patients with Early Rheumatoid Arthritis; Findings Reported at the American College of Rheumatology (ACR)
Not unlike cancer, disease outcome can be dramatically improved if RA is caught and treated early. Augurex Life Sciences Corp. reported that in Chicago at the American College of Rheumatology (ACR) Annual Scientific Meeting, world-leading arthritis researchers from...
Augurex Reports Positive Data for RA Blood Test and Drug Target at the Annual European Congress of Rheumatology (EULAR)
Company's novel biomarker and drug target could represent the first personalized medicine in RA promise for future targeted therapy in a multi-factorial disease. Augurex Life Sciences Corp. today reported that in London at the European League Against Rheumatism...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Home
Products
Science
About
News
Careers
Contact